GRAIL, LLC
1525 O'Brien Drive
Menlo Park
California
94025
United States
Tel: 833-694-2553
Website: https://grail.com/
Email: customerservice@grail.com
About GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.
LEADERSHIP:
CEO: Bob Ragusa
103 articles about GRAIL, LLC
-
GRAIL Poaches New CEO From Roche, Genentech
12/14/2017
Four months after Jeff Huber stepped down as CEO of GRAIL, the company has tapped his replacement. -
Vikram Bajaj joined Grail only a year ago.
-
Former Google Exec Steps Down as GRAIL CEO
8/4/2017
-
Scientists Move Closer To Detecting Cancer Long Before Any Symptoms Appear, GRAIL Reveals
6/12/2017
-
Bay Area GRAIL's Billion Gamble on the Perfect Cancer Test
6/7/2017
-
GRAIL Announces Data From Early Research Analyzing Its High-Intensity Sequencing Approach
6/5/2017
-
Cancer Screening Tie-up: Hong Kong's Cirina Merges With GRAIL, An Illumina Spin-Out
6/2/2017
-
Bay Area's GRAIL Goes Global, Merges With Hong Kong's Cirina to Focus on Cancer Detection
5/31/2017
-
GRAIL Announces Board Of Directors Appointments
5/4/2017
-
GRAIL Initiates The STRIVE Study To Advance Development Of Blood Tests To Detect Cancer Early
4/20/2017
-
A Closer Look at GRAIL, Illumina's Billion-Dollar Bay Area Diagnostics Startup
3/9/2017
-
What Illumina's And Bristol-Myers Squibb's Latest GRAIL Moves Mean For Investors
3/8/2017
-
Backed by Amazon and Big Names Like Bristol-Myers Squibb, Celgene and Merck & Co., Bay Area's GRAIL Banks $900 Million
3/3/2017
-
Bristol-Myers Squibb Release: Investment And Planned Collaboration With GRAIL On Blood-Based Cancer Screening
3/1/2017
-
What You Need to Know About GRAIL
1/16/2017
-
Why I'm Wary Of GRAIL And Its Plan To Develop A Cancer Blood Test
1/9/2017
-
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
-
Illumina-Backed GRAIL Eyes $1 Billion Funding Round for Cancer DNA Test
1/6/2017
-
GRAIL Announces Circulating Cell-free Genome Atlas (CCGA) Study As Foundation For Development Of Blood Test To Detect Cancer Early
12/1/2016
-
Illumina's GRAIL and the $200 Billion Market They are Eyeing
10/19/2016